COBRE Center for Cancer Research Development

 描述（由申请人提供）：COBRE癌症研究发展中心（CCRD）已成为RIH癌症研究基础设施资源和环境的组成部分。我们的第一阶段和第二阶段的特点是优秀的初级研究者生产力方面的同行评审的出版物（n=145）和成功获得校外，联邦资金（23,265,020美元）。第一阶段和第二阶段奖项的最初科学主题是强调对癌症及其起源机制的研究。通过新的试点赠款核心，继续刺激对癌症感兴趣的初级研究者获得奖励和核心用户信用，从而在第三期COBRE中保持对癌症生物学的关注。在过去的五年里，RIH在癌症的临床和基础研究方面进行了大量的机构投资。调查的增加对CCRD核心设施产生了积极影响，因为它增加了当地客户群。这一扩大的客户基础将被纳入一项战略计划，以便在第三阶段之后利用强大的机构资金维持CCRD核心设施。提出了以下四个目标：（目标1）通过成熟分子病理学和蛋白质组学核心，继续提高管理核心监督COBRE CCRD目标的能力，减少III期对NIH支持的依赖。(Aim 2）继续保持蛋白质组学核心设施在快速发展的质谱技术与全球蛋白质组学和鉴定分离或组织内的候选蛋白质的前沿。(Aim 3）提供分子病理学服务，包括存档的肿瘤库标本，以提高各级专业研究人员的生产力和研究能力，以解决研究问题，并提高他们对校外资助的竞争力。(Aim 4）提供试点赠款和核心用户信用，专门支持对癌症研究感兴趣的初级研究人员，并为试点奖得主提供生物信息学分析。

 DESCRIPTION (provided by applicant): The COBRE Center for Cancer Research Development (CCRD) has become an integral part of the resources and environment of the cancer research infrastructure at RIH. Our Phase I and II periods were characterized by outstanding junior investigator productivity in terms of peer reviewed publications (n=145) and success in obtaining extramural, federal funding ($23,265,020.) The original scientific theme of the Phase I and Phase II awards was to emphasize research on mechanisms of cancer and its origins. This focus on cancer biology will be maintained through the Phase III COBRE by continuing to stimulate awards and core user credits to junior investigators interested in cancer through a new Pilot Grants Core. During the past five years RIH has made a substantial institutional investment in clinical and basic research in cancer. This increase in investigation has had a positive effect on the CCRD Core facilities as it has created an increased local customer base. This expanded customer base will be factored into a strategic plan for sustaining the CCRD core facilities beyond the Phase III period with strong institutional funding. The following four aims are proposed: (Aim 1) To continue to enhance the ability of the Administrative Core to oversee the goals of the COBRE CCRD through maturing of the Molecular Pathology and Proteomics Cores with less reliance on NIH support during Phase III. (Aim 2) To continue to keep the Proteomics Core facility at the cutting edge of rapidly evolving mass spectroscopic technologies associated with global proteomics and identification of candidate proteins in isolation or within tissues. (Aim 3) To provide molecular pathology services including archived tumor bank specimens for enhancing productivity and research capabilities of investigators at all levels of expertise in order to address research problems and to increase their competitiveness for extramural funding. (Aim 4) To provide pilot grants and core user credits to solely support junior investigators interested in cancer research and to offer bioinformatic analysis to recipients of pilot awards.